Cargando…

Low Dose Ribavirin for Treatment of Hepatitis C Virus Infected Thalassemia Major Patients; New Indications for Combination Therapy

BACKGROUND: Treatment guidelines contraindicate ribavirin for treatment of hepatitis C virus (HCV) infection in thalassemia major patients. Nevertheless, the current evidence suggests that ribavirin might be tolerated by these patients. OBJECTIVES: Despite this evidence, low dose ribavirin combinati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tabatabaei, Seyed Vahid, Alavian, Seyed Moayed, Keshvari, Maryam, Behnava, Bita, Miri, Seyyed Mohammad, Karimi Elizee, Pegah, Zamani, Farhad, Amini Kafiabad, Sedigheh, Gharehbaghian, Ahmad, Hajibeigy, Bashir, Lankarani, Kamran Bagheri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412553/ https://www.ncbi.nlm.nih.gov/pubmed/22879826 http://dx.doi.org/10.5812/hepatmon.6592

Ejemplares similares

Cost-Effectiveness Analysis of Adding Low Dose Ribavirin to Peginterferon Alfa-2a for Treatment of Chronic Hepatitis C Infected Thalassemia Major Patients in Iran
por: Mehrazmay, Alireza, et al.
Publicado: (2013)

Lipid Profiles and Hepatitis C Viral Markers in HCV-Infected Thalassemic Patients
por: Alavian, Seyed-Moayed, et al.
Publicado: (2011)

Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy
por: Sandoughdaran, Saleh, et al.
Publicado: (2015)

The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C
por: Behnava, Bita, et al.
Publicado: (2016)

Plasma Zinc Level in Hepatitis C Patients With or Without Beta Thalassemia Major; Is There Any Difference?
por: Abbasinazari, Mohammad, et al.
Publicado: (2013)

Letter to the Editor: The Increasing Hepatitis A Incidence in Korea: Is It Possible Within a Limited Time?
por: Elizee, Pegah Karimi, et al.
Publicado: (2012)

The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C
por: Keshvari, Maryam, et al.
Publicado: (2016)

The Prevalence of Hepatitis C Virus Core Amino Acid 70 Substitution and Genotypes of Polymorphisms Near the IFNL3 Gene in Iranian Patients With Chronic Hepatitis C
por: Kadjbaf, Danesh, et al.
Publicado: (2016)

The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C
por: Pouryasin, Mohammad, et al.
Publicado: (2016)

Prevention of Hepatitis A Virus Infection, Need to Vaccinate or Not?
por: Elizee, Pegah Karimi, et al.
Publicado: (2013)

The Comparative Efficacy and Safety of Peginterferon Alpha-2a vs. 2b for the Treatment of Chronic HCV Infection: A Meta-Analysis
por: Alavian, Seyed Moayed, et al.
Publicado: (2010)

Optimal Duration of Treatment for HCV Genotype 1 Infection in Slow Responders: A Meta-Analysis
por: Alavian, Seyed Moayed, et al.
Publicado: (2011)

Standard and pegylated interferon therapy of HDV infection: A systematic review and meta- analysis
por: Alavian, Seyed-Moayed, et al.
Publicado: (2012)

Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials
por: Aminizadeh, Ehsan, et al.
Publicado: (2016)

The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study
por: Sharafi, Heidar, et al.
Publicado: (2014)

A Woman with Recent Jaundice and Pruritus
por: Behnava, Bita, et al.
Publicado: (2010)

Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis
por: Dolatimehr, Fardin, et al.
Publicado: (2017)

Seroprevalence of Hepatitis B Virus Infection and Its Risk Factors in the West of Iran: A Population-based Study
por: Alavian, Seyed Moayed, et al.
Publicado: (2012)

Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1
por: Sharafi, Heidar, et al.
Publicado: (2015)

IL28B SNP genotyping among Iranian HCV-infected patients: A preliminary report
por: Mahboobi, Nastaran, et al.
Publicado: (2011)

Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response
por: Sharafi, Heidar, et al.
Publicado: (2012)

Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals
por: Sharafi, Heidar, et al.
Publicado: (2012)

Mysterious Linkages Between Hepatitis C Virus Genotypes, Interleukin-28B Genotypes and Viral Clearance- A Meta-Analysis
por: Aalaei-Andabili, Seyed Hossein, et al.
Publicado: (2014)

Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study
por: Sharafi, Heidar, et al.
Publicado: (2020)

Associates of poor physical and mental health-related quality of life in beta thalassemia-major/intermedia
por: Azarkeivan, Azita, et al.
Publicado: (2009)

Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleoside-Analogue Naive Iranian Patients Treated for Chronic Hepatitis B
por: Bakhshizadeh, Fatemeh, et al.
Publicado: (2015)

Real Response to Therapy in Chronic Hepatitis C Virus Patients: A Study From Iran
por: Namazee, Najmeh, et al.
Publicado: (2012)

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

High Rate of Virological Response to Peginterferon α-2a–Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C
por: Alavi Moghaddam, Mostafa, et al.
Publicado: (2012)

Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?
por: Pourhoseingholi, Mohamad Amin, et al.
Publicado: (2014)

Eradication of hepatitis C virus infection in thalassemia patients in Iran using various treatment strategies
por: Moghimbeygi, Meisam, et al.
Publicado: (2020)

The More Publication, the Higher Impact Factor: Citation Analysis of Top Nine Gastroenterology and Hepatology Journals
por: Karimi Elizee, Pegah, et al.
Publicado: (2012)

How Can We Make Decision for Patients With Chronic Hepatitis B According to Hepatitis B Virus (HBV) DNA Level?
por: Keshvari, Maryam, et al.
Publicado: (2014)

What is the ethnicity-specific impact of genetic polymorphisms on the response to hepatitis C treatment in an admixed population of Brazilian patients?
por: Keshvari, Maryam, et al.
Publicado: (2014)

Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients
por: Keshvari, Maryam, et al.
Publicado: (2015)

Interferon Alpha-2b Therapy in Chronic Hepatitis Delta
por: Keshvari, Maryam, et al.
Publicado: (2014)

Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders
por: Sharafi, Heidar, et al.
Publicado: (2021)

Lessons learned from past cholera epidemics, interventions which are needed today
por: Lankarani, Kamran B, et al.
Publicado: (2013)

Impact of Pegylated Interferon-alfa-2a on Perforin Level in Patients With Chronic Hepatitis B; Preliminary Study
por: Mahdavi, Meisam, et al.
Publicado: (2013)

Risk factors of hepatitis B infection: Health policy makers should be aware of their importance in each community
por: Miri, Seyed Mohammad, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_39g0bmuna9b58lgps9nnquuib1